Program and Platform Status.
A focused view of Macro HRD's therapeutic programs, platform technologies, and current development status.
MACR - 001 Trispecific Antibody HIV / AIDS HIV reservoir-directed therapeutic
HIV reservoir-directed therapeutic program.
Trispecific antibody, bNAb x CD3 x CD28.
Reservoir-directed clearance of HIV-infected cells, with emphasis on HIV Env recognition, CD3 engagement, and CD28 co-stimulatory logic.
Trispecific construct design and in-vitro engagement remain the central disclosed development focus.
Topical Spray/Gel MACR - 002 HPV/Cervical Cancer Genital mucosal epithelial delivery
Topical mucosal strategy for genital mucosal environments.
Topical peptide spray / gel strategy.
Non-enveloped virus; mucosal retention, epithelial delivery, local microenvironment targeting, and HPV-specific evidence.
The program is organized around local mucosal delivery rather than lipid-envelope disruption.
Advanced Lipid Nanoparticle Delivery Platform MACR - 003 CNS Delivery Cross the Blood-Brain Barrier (BBB)
Enabling formulation platform for selected payload and tissue-access needs.
Delivery platform.
Formulation support for payload, route, tissue-access, and residence-time needs where delivery is limiting.
Research-stage imaging supports continued evaluation of organ-directed formulation behavior.
AH-D Enveloped Peptides MACR - 004 Broad-Spectrum Antiviral Enveloped viruses – Zika, dengue, Ebola, influenza, coronaviruses & more
Zika, dengue, chikungunya, yellow fever, Japanese encephalitis, influenza, coronaviruses, Ebola, and other enveloped viruses.
Membrane-active peptide.
Curvature-dependent lipid-envelope disruption for enveloped viruses. The free peptide is active on its own; LNP is optional formulation support.
Published in-vitro / in-vivo activity supports the scientific rationale for enveloped-virus applications.
Published studies provide scientific rationale where applicable, while Macro HRD-owned development progress is presented separately through program-specific disclosures.
Programs presented with clear scientific and development context.
Program information separates published scientific rationale from Macro HRD-owned development progress.
Public-stage placement by current program status.
Discovery -> Lead Optimization -> Preclinical -> IND-enabling -> Phase 1. Public-stage placement is based on disclosed program context and published scientific rationale where applicable.
Discovery: HPV Topical and formulation concepts requiring HPV-specific evidence.
Lead Optimization: HIV trispecific antibody construct design and engagement work, with continued development focused on reservoir-directed therapeutic logic.
Preclinical: AH-D enveloped-virus rationale and Advanced LNP delivery research support continued platform development.